SCPH scPharmaceuticals
- 3.380
- -0.040-1.17%
scPharmaceuticals News
TD Cowen Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $25
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Craig-Hallum Issues a Buy Rating on ScPharmaceuticals (SCPH)
Jefferies Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Cuts Target Price to $13
Maxim Group Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $20
Positive Outlook for ScPharmaceuticals: Strategic Growth and Regulatory Milestones Drive Buy Rating
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and ScPharmaceuticals (SCPH)
ScPharmaceuticals Analyst Ratings
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Announces Target Price $12
TD Cowen Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $18
TD Cowen Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $25
Positive Buy Rating for ScPharmaceuticals Driven by Strong Furoscix Launch and Strategic Growth Initiatives
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Leerink Partners Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $20
Strategic Growth and Market Expansion Opportunities Drive Buy Rating for ScPharmaceuticals
Maxim Group Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $20
Strategic Buy Rating for ScPharmaceuticals: Furoscix's Potential in CKD Market
No Data